Uveal melanoma is difficult to treat successfully. Pasireotide (SOM230) is an investigational targeted therapy that binds to proteins called somatostatin receptors. Everolimus is an oral drug that inhibits a molecule called mTOR, which helps cancer cells grow. Everolimus is approved for the treatment of renal cell carcinoma, but its use for treating uveal melanoma is considered investigational.
Researchers believe that both somatostatin receptors and mTOR are important for the growth of uveal melanoma. They hope that by blocking both proteins, they can prevent tumor growth or cause tumors to shrink. The purpose of this study is to evaluate the safety and effectiveness of combining pasireotide and everolimus in patients with uveal melanoma that has spread or has not responded to treatment.